{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-24-000055","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.360780+00:00","generated_at":"2026-05-31T11:49:45.883671+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel","bullets":["Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.","Cash, equivalents and investments $444.6M as of June 30, 2024; runway into 2H 2026.","Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL initiated; enrollment completion expected 1H 2026, BLA submission 2027.","ALLO-329 (CD19/CD70 dual CAR) IND on track for Q1 2025 in autoimmune disease; proof-of-concept by YE 2025.","ALLO-316 Phase 1 TRAVERSE data update with ~20 RCC patients planned for YE 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-24-000055","json":"https://secwatch.observer/filing/0001737287-24-000055.json","markdown":"https://secwatch.observer/filing/0001737287-24-000055.md","text":"https://secwatch.observer/filing/0001737287-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000055/0001737287-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000055/allo-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:49:45.883671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}